Disc Medicine Announces Underwritten Offering of Common Stock

Company Overview - Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases [9]. Recent Offering - Disc announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share, with expected gross proceeds of approximately $178.0 million before deductions [3]. - The offering is expected to close on June 17, 2024, subject to customary closing conditions [3]. Use of Proceeds - The net proceeds from the offering will be used to fund research and clinical development of current or additional product candidates, as well as for working capital and other general corporate purposes [2]. Financing Details - The financing was led by Frazier Life Sciences and Logos Capital, with participation from various institutional investors including Access Biotechnology and Wellington Management [7]. Regulatory Information - The securities are being offered pursuant to a shelf registration statement on Form S-3, which was declared effective by the SEC on November 29, 2023 [8].